PDL1 (SP263)

Brief about this service

Offered for cases where PD-L1 expression evaluation is requested as part of treatment-pathway planning.

PDL1 SP263 assay support with standardized interpretive reporting. Each case is processed under quality-controlled oncology diagnostics workflows for clinically meaningful output.

When this test is commonly used

• Cases where PD-L1 expression scoring is requested for treatment discussions.
• SP263 assay workflows requiring standardized staining and reporting language.
• Oncology settings where biomarker reporting consistency is essential.

Sample and reporting guidance

Provide representative tissue sections or blocks with relevant histology context so marker interpretation can be correlated accurately with morphology.

Reports are structured for doctor readability with concise interpretation notes and pathway-oriented communication.